Aim: To assess the associations of baseline and long-term gamma-glutamyltransferase (GGT) activity with risk of heart failure (HF), ventricular arrhythmias (VAs) and atrial fibrillation (AF). Methods: GGT measurements were made in a prospective cohort of 1780 men free of HF and cardiac arrhythmias at baseline. Correction for within-person variability was made using data from repeat measurements taken several years apart. Results: During an average follow-up of 22 years, 222 HF, 56 VA and 336 AF events occurred. The regression dilution ratio of log e GGT was 0.68 (95% confidence interval (CI): 0.61-0.74). Serum GGT was log-linearly associated with risk of HF, VAs and AF. In analyses adjusted for established risk factors, the hazard ratios (HRs) (95% CIs) for HF, VAs and AF per 1 SD higher baseline log e GGT values were 1.25 (1.07-1.45), 1.37 (1.04-1.80) and 1.04 (0.92-1.18), respectively. After correction for within-person variability, the corresponding HRs were 1.38 (1.11-1.73), 1.58 (1.06-2.37) and 1.06 (0.88-1.27), respectively. These findings remained consistent in analyses accounting for incident coronary heart disease and the development of impaired renal function. In a meta-analysis of five population-based studies, the fully adjusted relative risks for HF per 1 SD higher baseline and long-term GGT values were 1.28 (1.20-1.35) and 1.43 (1.31-1.56), respectively. In a pooled analysis of two studies, the corresponding risks for AF were 1.09 (1.02-1.16) and 1.14 (1.03-1.25), respectively. Conclusion: GGT is positively and log-linearly associated with future risk of HF, VAs and AF. Further research is needed in order to assess the causal relevance of these findings.
Introduction
Gamma-glutamyltransferase (GGT) activity has been routinely used in clinical practice in order to help indicate potential hepatic or biliary disease. 1 Elevated GGT values may also reflect the accumulation of hepatic fat, 2 oxidative stress 3 and have been shown to be associated with cardiovascular disease (CVD) outcomes. Several prospective studies have consistently demonstrated associations between GGT and risk of coronary heart disease (CHD), 4 stroke, 4 CVD mortality 5 and composite CVD events. 4, 6 However, uncertainty persists regarding the association of GGT with heart failure (HF) and cardiac arrhythmias (ventricular arrhythmias (VAs) and atrial fibrillation (AF)). HF is associated with unacceptably high morbidity and mortality risks 7 and imposes a significant economic burden on health systems. Cardiac rhythm disturbances, with AF being the most commonly diagnosed arrhythmia in clinical practice, are considered to be the final events in a chain of complications leading to stroke and increased overall mortality. 8 Cardiac arrhythmias and HF often coexist and share many common risk factors such as older age, hypertension, myocardial infarction and diabetes. 9 Both VAs and AF are associated with an increased risk of HF events and vice versa, with death being a common consequence. 10 Although a number of population-based prospective studies have shown a positive association between baseline GGT activity and risk of HF events, 5, 11, 12 no study has yet assessed the long-term relevance of GGT activity to HF. There is very little information regarding the extent to which GGT fluctuates within individuals, as these data enhance the interpretation of epidemiological studies with an aetiological motivation. We have recently shown that GGT exhibits high within-person variability, 13 which could be the result of measurement errors in assays, fluctuations due to acute-phase reactions, lifestyle changes, ageing and chronic disease. Therefore, analysis using only baseline measurements of GGT might underestimate the true strength of any aetiological association between GGT and disease outcome (i.e. 'regression dilution bias'). 14 Previous studies may have considerably underestimated the association between GGT and HF; therefore, there is a need to estimate and correct for the effect of this regression dilution bias. Prospective data regarding the association between GGT and AF are sparse; Alonso and colleagues in the Atherosclerosis Risk in Communities (ARIC) study reported an association between GGT activity and an increased risk of AF. 15 However, to our knowledge, the prospective association between GGT and risk of VAs has not been previously investigated.
Against this background, we aimed to quantify the associations of GGT with risks of HF, VAs and AF more reliably than has been previously possible in a population-based cohort of 1780 apparently healthy men from eastern Finland. To put our results into context, we also performed pooled analyses of the available published prospective evidence relating to these associations.
Methods
Details of study population, endpoint ascertainment, risk factor assessment, statistical analyses and literature search strategy can be found in Supplementary Materials 1 and 2. Table 1 summarizes the baseline characteristics of the 1780 participants in the Kuopio Ischaemic Heart Disease (KIHD) study. The mean age of the participants was 53 (SD: 5) years. The median (interquartile range) GGT value was 20 (15-32) U/L. During an average follow-up of 22 years, there were 222 HF events (annual rate: 5.67/1000 person-years at risk; 95% confidence interval (CI): 4.97-6.47); 56 incident VAs (annual rate: 1.42/1000 person-years at risk; 95% CI: 1.09-1.84); and 336 incident AF events (annual rate: 8.93/1000 person-years at risk; 95% CI: 8.03-9.94). Serum GGT values were weakly to moderately and positively correlated with physical measures (body mass index (BMI), blood pressure and resting heart rate) and with several lipid, metabolic and inflammatory markers. Weak inverse correlations were observed for age (r ¼ À0.03) and high-density lipoprotein cholesterol (HDL-C) (r ¼ À0.04). Baseline GGT values were higher in men with diabetes compared to men without diabetes, higher in men with a history of hypertension compared to men without a history of hypertension and higher in current smokers compared to non-smokers.
Results

Baseline characteristics and correlates of GGT
Correction for within-person variability
Repeat measurements of GGT taken 4 years and 11 years after baseline were available in a random sample of 624 men, yielding a total of 1143 repeat measurements of GGT. Overall, the regression dilution ratio of log e GGT, adjusted for age, was 0.68 (95% CI: 0.61-0.74), suggesting that the associations using one-off or baseline measurements of GGT with the outcomes could be underestimated by ((1/0.68) À 1) Â 100 ¼ 47%.
GGT and risk of HF
Prospective cohort analysis. In analyses adjusted for conventional risk factors (age, BMI, systolic blood pressure, prevalent CHD, smoking status, history of diabetes mellitus, left ventricular hypertrophy (LVH) and use of antihypertensive agents and lipid-lowering drugs), there was a log-linear association between GGT and HF risk (Figure 1 ; Supplementary Materials 3 and 4). The age-adjusted hazard ratio (HR) per 1 SD change in log e GGT value was 1.45 (95% CI: 1.28-1.67; p < 0.001), which was somewhat attenuated to 1.25 (95% CI: 1.07-1.45; p ¼ 0.004) following further , and the main results remained similar in analyses that excluded the first 5 years of follow-up, participants with GGT values greater than three-times the upper limit of normal and participants with potential fatty liver disease (data not shown). In subsidiary analyses, we found significant evidence of associations of GGT with CVD mortality and nonfatal HF ( Supplementary Materials 6 and 7) .
Literature-based meta-analysis. Including the current study, we identified five population-based prospective studies 5, 11, 12, 16 reporting on the association between GGT and HF risk ( Supplementary Materials 8 and 9 ). In a pooled analysis of 210,841 participants and 1821 HF events, the relative risks (RRs) for HF per 1 SD higher baseline and usual GGT values, typically adjusted for several conventional and emerging risk factors, were 1.28 (95% CI: 1.20-1.35; p < 0.001) and 1.43 (95% CI: 1.31-1.56; p < 0.001), respectively ( Figure 2 ). The summary RR was identical when a fixed-effect model was employed. Exclusion of any single study at a time from the pooled analysis had minimal effect on the pooled RR. We found no evidence of heterogeneity among the contributing studies (I 2 ¼ 0%; p ¼ 0.791). 
Association of GGT with risk of cardiac arrhythmias
In analyses adjusted for conventional risk factors, there was an approximately log-linear association between GGT and VAs (Figure 1; Supplementary Materials 3  and 4 ). The age-adjusted HR for VAs per 1 SD change in baseline log e GGT value was 1.48 (95% CI: 1.16-1.90; p ¼ 0.002), which was minimally attenuated following further adjustment for established risk factors to 1.37 (95% CI: 1.04-1.80; p ¼ 0.026). Similarly adjusted HRs per 1 SD change in usual log e GGT values were 1.78 (95% CI: 1.24-2.56; p ¼ 0.002) and 1.58 (95% CI: 1.06-2.37; p ¼ 0.026), respectively. The results were somewhat attenuated on further adjustment for alcohol consumption, resting heart rate, triglycerides, total cholesterol, HDL-C and eGFR and remained consistent on further adjustment for CRP and accounting for incident coronary events ( Table 2 ). The HRs did not vary significantly by levels or categories of pre-specified conventional risk factors (p for interaction > 0.10 for each) ( Supplementary Material 10) . While there was a log-linear positive association of GGT with AF risk in analyses that were initially adjusted for age, the association was less robust on further adjustment for conventional risk factors (Figure 1 ; Supplementary Materials 3 and 4; Table 2 ). In a pooled analysis of the KIHD and ARIC studies (11, 113 participants and 1357 AF cases), the fully adjusted HRs for AF per 1 SD higher baseline and usual GGT values were 1.09 (95% CI: 1.02-1.16; p ¼ 0.008) and 1.14 (95% CI: 1.03-1.25; p ¼ 0.008).
Discussion
In addition to assessing the shape and magnitude of the prospective associations of baseline GGT activity with HF and AF, our study is the first to evaluate these aspects of the association of GGT with risk of VAs. By correcting for regression dilution using repeat measurement of GGT, we have also shown that these associations are considerably underestimated (by approximately half) when baseline measurements of GGT are used. In this population of middle-aged men without HF and a history of cardiac arrhythmias at baseline, while GGT was positively and log-linearly associated with risks of HF and VAs in analyses that were adjusted for several conventional risk factors, the initial positive log-linear association of GGT with risk of AF in the age-adjusted analysis was somewhat attenuated upon further adjustment for conventional risk factors. In the ARIC study, Alonso and colleagues have also demonstrated a linear relationship for the association between GGT and AF, but their association remained independent of several potential confounders, including incident coronary artery disease events as a time-dependent covariate. 15 However, in our pooled analysis of the two studies, there was a statistically significant association between GGT and AF. Our findings remained consistent across several subgroups and levels of cardiovascular risk markers and were unchanged in analyses that adjusted for CHD and impaired renal function during follow-up and in several sensitivity analyses. Pooled findings from the meta-analysis of five studies reinforces the validity and generalizability of the GGT-HF association, suggesting that a twofold increase in usual GGT values is associated with an approximately 40% higher risk of HF. However, given the high mortality rate in our study cohort, which might have impacted our event of interest, the association between GGT and HF was attenuated when death was adjusted for as a competing risk event. This was not a surprising finding, as total deaths in the cohort included CVD mortality events, and our subsidiary analysis demonstrated GGT to be associated with CVD mortality.
Possible explanations for the findings
The proposed mechanistic pathways underpinning the associations of elevated GGT values and increased risks of HF and cardiac arrhythmias include the pro-oxidant and pro-inflammatory activities 17 of GGT and its direct involvement in atheromatous plaque formation. 18 Other pathways that have been implicated include underlying fatty liver, 17 which is associated with lowgrade inflammation, insulin resistance and oxidative stress, 19, 20 all of which are known to be associated with increased risk of these cardiovascular outcomes. [21] [22] [23] Endothelial dysfunction and exposure to environmental pollutants have also been postulated. 24, 25 Given that CHD is a major cause of HF 26 and the consistent observational association that has been demonstrated between GGT and CHD, 27 underlying CHD may be mediating the association between GGT and HF. However, our association between GGT and HF remained persistent upon accounting for incident CHD during follow-up. There is also a possibility that the association between GGT and HF may be due to reverse causation, as GGT is frequently increased in HF due to the liver dysfunction that is commonly encountered in HF. 28 However, this is unlikely given: (i) that our analysis was pre-specified to include participants without a history of HF at baseline; (ii) the mean followup period (>20 years) was sufficiently long to ascertain the risk of HF; and (iii) the findings remained robust upon excluding the first 5 years of follow-up. In addition, given that GGT is also synthesized by the kidneys, there is a close relationship with renal function; therefore, the association of GGT with HF may also reflect impaired renal function. 29 Our findings, however, remained largely unchanged after adjusting for baseline renal function and accounting for the development of impaired renal function. The robust linear and independent relationships that have been demonstrated are suggestive of causality, but these require confirmation in robust randomized controlled trials. There are several pharmacological agents (e.g. insulin sensitizers and antioxidants) that modify levels of GGT; however, they also alter the levels of other liver enzymes and lipid factors. 30 In the absence of clinical trials, however, Mendelian randomization studies of genetic variants that are specifically related to GGT levels may provide another route to assessing causality. 31 
Implications of the findings
Our findings are relevant and may have clinical implications. They further extend the evidence base and thus highlight a clear link between serum GGT and the development of cardiovascular outcomes. The findings underscore a potentially deleterious role of increasing GGT activity on future risk of a wide range of adverse cardiovascular outcomes in the general population. Given that the assays for GGT are sensitive, well standardized, simple, quick, inexpensive, commonly measured as part of routine liver function panels and do not require a fasting state prior to venepuncture, they have the potential to be used in the identification of individuals who are at high risk of these adverse cardiovascular outcomes and in developing treatment methods. However, additional research is needed in order to help discover the mechanistic pathways of GGT in the pathogenesis of cardiovascular outcomes, and larger studies are needed to confirm these findings.
Strengths and limitations
The notable strengths of this research include a large sample that was selected to be a nationally representative population-based sample of middle-aged men, was well characterized, elicited high response levels and there were no losses during follow-up, reducing the risk of selection bias. Participants have been prospectively monitored using established databases for hospital admissions, supplemented with reliable data on a comprehensive panel of lifestyle and biological markers, including medication for hypertension and dyslipidaemia, in order to allow for adequate adjustment for potential confounding, enabling reliable and independent assessments of the associations. The mean follow-up period was sufficiently long to ascertain the risk of the various endpoints in the general population. Repeat measurements of GGT made within the same individuals over time were available, enabling correction for within-person variability. Several sensitivity analyses were conducted in order to ensure the robustness of our results. To put our GGT-HF results into context, we conducted a meta-analysis of five studies (including the present study) and demonstrated the reliability of our cohort analyses. The limitations of the present study also deserve mention. We were unable to assess the differential impact of GGT on the risk of HF with preserved versus reduced ejection fractions because there were no data on ventricular function post-HF development. There was no detailed information on whether cardiac arrhythmic events were paroxysmal (or treated by cardioversion) because arrhythmias were based on hospitalization data. However, we detected the clinically most important arrhythmic events. There is a possibility that very short events of VAs and AF might have been missed without continuous heart rhythm monitoring systems in place. In the KIHD study, the majority of sudden cardiac deaths (SCDs) that occurred during follow-up happened out of hospital ($80%); 13 therefore, it was not possible to detect all cases of VAs, given that SCD is generally considered to be a complication of ventricular fibrillation/tachycardia. In addition, ascertainment of arrhythmic events relied substantially on hospitalization discharge codes, potentially missing cases that were asymptomatic. However, the validity of this approach for epidemiological studies of this nature has been demonstrated to be adequate. 32, 33 Although a comprehensive panel of confounders was taken into account in order to ensure the validity of our results, potential residual confounding due to other unmeasured confounders (such as antioxidants and other medications such as phenytoin or barbiturates that affect baseline levels of GGT) cannot be entirely ruled out. Measurements of other liver function enzymes such as the aminotransferases were not made in the KIHD study, preventing comparison of the separate and joint associations of different liver function enzymes with the outcomes assessed. The study included only middle-aged Finnish men from eastern Finland and cannot necessarily be extrapolated to the young, to women or to other populations. However, the pooled analyses for the GGT-HF and GGT-AF associations involved studies that were conducted in both men and women.
Conclusions
GGT activity is positively and log-linearly associated with future risk of HF, VAs and AF. Further research is needed in order to assess the causal relevance of these findings.
